Clinical Trial Update: Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement [Phase 2]

View source ↗

Summary

Phase 2 study evaluating Futibatinib in patients with advanced cholangiocarcinoma harboring FGFR2 fusions; trial status is recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• Futibatinib (futibatinib)

Snippet

Sponsor: Taiho Oncology, Inc. | Conditions: Advanced Cholangiocarcinoma, FGFR2 Fusions | Phase 2 | Status: RECRUITING